Real-world Canadian Retrospective Study Evaluating Longitudinal Semaglutide Use on Cardio-Kidney-Metabolic Outcomes

Sponsor
LMC Diabetes & Endocrinology Ltd.
Study ID
NCT07424430
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this study is to better understand the real-world effectiveness of semaglutide use on cardio-kidney-metabolic outcomes among adults with T2D and adults with obesity (without diabetes mellitus). This is a retrospective longitudinal analysis using the LMC Diabetes Registry. The primary outcome of the study is to evaluate the change in HbA1c between baseline to 3 years of follow-up among adults with T2D who initiated semaglutide compared to adults with T2D who initiated other AHAs, including sulfonylurea, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors.

Key Dates

Start date
Mar 31, 2026
Status verified
Feb 2026
Primary completion
Apr 30, 2026
Completion
May 31, 2026

Study Design

Enrollment
400 participants (estimated)

Arms

  • Arm: T2D Semaglutide Cohort
    Adults with T2D prescribed semaglutide
  • Arm: T2D other AHA cohort
    Adults with T2D prescribed antihyperglycemic medication beside semaglutide including sulfonylurea, DPP4i, and/or SGLT2i
  • Arm: Obesity Semaglutide Cohort
    Adults with obesity, defined as BMI equal or greater than 27 kg/m2, prescribed semaglutide

Primary Outcome Measure

Change in HbA1c- 3 Years [ Time Frame: Baseline to 3 Years ]

Central Contacts

Related Studies